AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, I.
Right arrow Articles by Fujie, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, I.
Right arrow Articles by Fujie, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2005, p. 3053-3055, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3053-3055.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Prevention of the Cryptic Epitope SLAYGLR within Osteopontin Does Not Influence Susceptibility to Candida albicans Infection

Ikuko Sato,1* Nobuchika Yamamoto,2 Harumi Yamazaki,2 Seiji Hashimoto,1 Motohiro Hino,1 Fumihiko Sakai,2 and Akihiko Fujie1

Fermentation Research Laboratories,1 Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 5-2-3 Tokodai, Tsukuba, Ibaraki, 300-2698, Japan2

Received 25 August 2004/ Returned for modification 31 December 2004/ Accepted 27 March 2005

The effect of an antiosteopontin antibody (M5 Ab) reacting with the SLAYGLR sequence within osteopontin on the host susceptibility to infection was investigated in a murine model of disseminated candidiasis. The treatment with anti-tumor necrosis factor alpha antibody enhanced fungal infection, while the treatment with M5 Ab did not affect the infection.

* Corresponding author. Mailing address: Fermentation Research Laboratories, Astellas Pharma Inc., 5-2-3 Tokodai, Tsukuba, Ibaraki, 300-2698, Japan. Phone: 81-29-847-8611. Fax: 81-29-847-8313. E-mail: ikuko.sato{at}jp.astellas.com.

Antimicrobial Agents and Chemotherapy, July 2005, p. 3053-3055, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3053-3055.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.